Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haitripopa plus rhTPO vs monotherapy for platelet reconstruction after autologous HSCT in lymphoma
ChiCTR2200059894Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in lymphoma and Thrombocytopenia comparing Haitripopa + rhTPO, rhTPO monotherapy and Haitripopa monotherapy (3 arms). Primary endpoint: Hematopoietic reconstruction time. Started Apr 2022; status: recruiting.
02
Drugs
Haitripoparecombinant human thrombopoietin
03
Conditions
lymphomaThrombocytopenia
Beyond the preview
Go deeper on ChiCTR2200059894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059894.